Cure My Disease

Don't miss your cure!

 Log in / Sign up

Asthma drug enerzair under Real-World watch

NCT ID NCT05274425

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks 600 adults with asthma who are already prescribed Enerzair inhaler. Over 24 weeks, researchers will monitor side effects and how well the drug controls asthma in everyday life. No new treatment is given; it simply observes routine care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Enerzair (indacaterol/glycopyrronium/mometasone) inhaler

What this could lead to

If successful, this study could confirm that Enerzair works well and is safe for everyday asthma control in a broad range of patients.

What could go wrong

This is an observational study, not a controlled trial, so results may be less reliable. It only follows patients for 24 weeks, so long-term effects are not assessed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTHMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Daegu, Dalseo gu, 42602, South Korea

  • Novartis Investigative Site

    RECRUITING

    Wŏnju, Gangwon-do, 26426, South Korea

  • Novartis Investigative Site

    COMPLETED

    Bucheon-si, Gyeonggi-do, 14584, South Korea

  • Novartis Investigative Site

    RECRUITING

    Bundang Gu, Gyeonggi-do, 13620, South Korea

  • Novartis Investigative Site

    COMPLETED

    Goyang-si, Gyeonggi-do, 10475, South Korea

  • Novartis Investigative Site

    RECRUITING

    Jeonju, Jeollabuk-do, 561 712, South Korea

  • Novartis Investigative Site

    COMPLETED

    Suncheon, Jeollanam-do, 540-719, South Korea

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Cheongju-si, North Chungcheong, 28644, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, Seoul, 06351, South Korea

  • Novartis Investigative Site

    RECRUITING

    Busan, 49201, South Korea

  • Novartis Investigative Site

    RECRUITING

    Daegu, 705703, South Korea

  • Novartis Investigative Site

    RECRUITING

    Gwangju, 501171, South Korea

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Gyeonggi-do, 14353, South Korea

  • Novartis Investigative Site

    RECRUITING

    Gyeongsangnam Do, 630-522, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Seoul, 03722, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 04763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 05505, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 06273, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 2447, South Korea